Begin typing your search...
Ocugen requests use of Covaxin for kids
Ocugen Inc., Bharat Biotech’s partner for USA and Canada for COVID-19 vaccine Covaxin on Friday said it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the jab for paediatric use.
By
migrator
migrator
Hyderabad
The submission is based on results of a Phase 2/3 paediatric clinical trial conducted by Bharat Biotech in India with 526 children 2-18 years of age, which bridged immunogenicity data to a large, Phase 3 safety and efficacy clinical trial in nearly 25,800 adults in India, Ocugen said in a regulatory filing. Some research suggests that people are seeking more choices when selecting a vaccine, especially for their children.
Visit news.dtnext.in to explore our interactive epaper!
Download the DT Next app for more exciting features!
Click here for iOS
Click here for Android
Next Story
